Views: 1,231 | Downloads:
26
| Responses: 0
| XML | Respond to this article | Alert & updates | Request permissions | Email to a friend |
Original ArticleOpen Access
Efficacy of Brimonidine 0.2 Per Cent as Adjunctive Therapy to Beta-Blockers: A Comparative Study between POAG and CACG in Asian Eyes
Ruangvaravate N 
,
Metheetrairut A ,
Kitl!arong N ,
Danwiriyakul W
,
Metheetrairut A ,
Kitl!arong N ,
Danwiriyakul W ANKANA METHEETRAIRUT, M.D.*,
WIMOLRA T DANWIRIY AKUL, B.Sc. **
Objective : To compare the efficacy and safety profile of brimonidine as adjunctive therapy
to beta-blockers between primary open angle glaucoma (POAG) and chronic angle closure glaucoma
(CACG) in Asian eyes.
Design : Three-months, open-label, prospective study.
Participants : Twenty-three patients (35 eyes) with POAG and 25 patients (39 eyes) with
CACG were enrolled in the study.
Intervention : Patients with POAG or CACG post iridectomy whose lOP was inadequately
controlled with topical beta-blocker monotherapy were included. Then, brimonidine 0.2 per cent was
added twice daily in both groups. Study visit occurred at weeks 2, 4, 8, and 12. Complete ophthalmic
examinations were performed in all visits.
Main Outcome Measures : Efficacy was determined by reduction in lOP from baseline and
tolerability was assessed by reports of adverse events.
Results : After 3 months of brimonidine adjunctive treatment, the mean
(เธ‘
SEM) lOP
reduction were 4.37
เธ‘
0.34 mmHg (19.4%) in POAG and 4.54
เธ‘
0.37 mmHg (20.1%) in CACG (p=
0.741). No serious ocular or systemic adverse event was reported.
Conclusion : Brimonidine was well tolerated, efficacious and provided additive lOP reduc-
tion in POAG and CACG.
Key word : Primary Open Angle Glaucoma (POAG), Chronic Angle Closure Glaucoma (CACG),
Topical Beta-Blocker, Brimonidine, Adjunctive Therapy
WIMOLRA T DANWIRIY AKUL, B.Sc. **
Objective : To compare the efficacy and safety profile of brimonidine as adjunctive therapy
to beta-blockers between primary open angle glaucoma (POAG) and chronic angle closure glaucoma
(CACG) in Asian eyes.
Design : Three-months, open-label, prospective study.
Participants : Twenty-three patients (35 eyes) with POAG and 25 patients (39 eyes) with
CACG were enrolled in the study.
Intervention : Patients with POAG or CACG post iridectomy whose lOP was inadequately
controlled with topical beta-blocker monotherapy were included. Then, brimonidine 0.2 per cent was
added twice daily in both groups. Study visit occurred at weeks 2, 4, 8, and 12. Complete ophthalmic
examinations were performed in all visits.
Main Outcome Measures : Efficacy was determined by reduction in lOP from baseline and
tolerability was assessed by reports of adverse events.
Results : After 3 months of brimonidine adjunctive treatment, the mean
(เธ‘
SEM) lOP
reduction were 4.37
เธ‘
0.34 mmHg (19.4%) in POAG and 4.54
เธ‘
0.37 mmHg (20.1%) in CACG (p=
0.741). No serious ocular or systemic adverse event was reported.
Conclusion : Brimonidine was well tolerated, efficacious and provided additive lOP reduc-
tion in POAG and CACG.
Key word : Primary Open Angle Glaucoma (POAG), Chronic Angle Closure Glaucoma (CACG),
Topical Beta-Blocker, Brimonidine, Adjunctive Therapy
Download:
PDF